Inozyme Pharma
About Inozyme Pharma
We are a pioneering, clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these metabolites. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.
Find Inozyme Pharma Execs' Valid Emails
Up to 90% verified emails and mobile numbers, refreshed weekly.
Company Details
10M-25M
Biotechnology Research
51-200 employees
Public Company
Boston, Massachusetts
United States
Frequently Asked Questions about
What is Inozyme Pharma's industry?
Inozyme Pharma operates in the Biotechnology Research industry and is headquartered in United States.
How many employees does Inozyme Pharma have?
Inozyme Pharma has approximately 51-200 employees employees.
Where is Inozyme Pharma's based?
Inozyme Pharma is based in Boston, Massachusetts, United States.
Is Inozyme Pharma publicly listed?
Yes. Inozyme Pharma is a publicly traded company.
How can I contact Inozyme Pharma's investor relations team?
You can reach Inozyme Pharma’s investor relations department through the contact section on their official website or directly via the investor relations email listed in their latest SEC filings.
Find verified emails and phone numbers for professionals like those at
Up to 90% verified emails and mobile numbers, backed by weekly job-change alerts.
Find verified emails at this company
An email pattern tells you the format. It does not tell you who works there now or whether an address still delivers. Scalelist returns verified contacts, checked at the point you build the list.